Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Teijin Pharma signs distribution agreements for febuxostat in multiple regions worldwide

April 19, 2011

Corcept Therapeutics submits NDA for Corlux in Cushing's syndrome

April 19, 2011

Novel neuropeptide Y2 receptor agonists presented by Novartis

April 19, 2011

Amarin's phase III ANCHOR trial of AMR-101 meets primary endpoint

April 18, 2011

CHMP recommends approval of once-weekly exenatide for type 2 diabetes

April 18, 2011

Preclinical data suggest benefit of allopurinol in diabetes-related nephropathy

April 15, 2011

TAK-075 is a new, stable, orally active bone anabolic agent for osteoporosis

April 15, 2011

FDA sets PDUFA date for Teva Pharma's Bio-T-Gel NDA

April 14, 2011

Primary efficacy objective met in phase III GetGoal-S trial of lixisenatide in type 2 diabetes

April 13, 2011

PROLOR reports promising phase II results on hGH-CTP in growth hormone deficiency

April 12, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...